Trial · NCT01532687
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | All randomized | 4.5 | 95% Confidence Interval 3.0 to 8.5 | months |
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Placebo | All randomized | 1.6 | 95% Confidence Interval 1.4 to 4.3 | months |
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Liposarcoma | 8.9 | 95% Confidence Interval 4.3 to NA | months |
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Placebo | Liposarcoma | 1.5 | 95% Confidence Interval 1.0 to NA | months |
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Other Sarcoma | 4.4 | 95% Confidence Interval 3.0 to 8.8 | months |
| Progression-free Survival (PFS) | Gemcitabine Hydrochloride Plus Placebo | Other Sarcoma | 2.2 | 95% Confidence Interval 1.4 to 4.6 | months |
Progression-free Survival (PFS) for a Sub-group of Patients Treated With Open-label Pazopanib Hydrochloride Following Administration of Gemcitabine Hydrochloride in the Cross-over Portion of This Study | Crossover From Gemcitabine + Placebo to Gemcitabine + Open-label Pazopanib | 3.0 | 95% Confidence Interval 1.3 to NA | months | |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | All randomized participants | 6.9 | 95% Confidence Interval 0.9 to 22.8 | percentage of participants |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Placebo | All randomized participants | 8.0 | 95% Confidence Interval 1.0 to 26.0 | percentage of participants |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Liposarcoma participants | 22.2 | 95% Confidence Interval 2.8 to 60 | percentage of participants |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Placebo | Liposarcoma participants | 0 | 95% Confidence Interval NA to NA | percentage of participants |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Other sarcoma participants | 0 | 95% Confidence Interval NA to NA | percentage of participants |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Gemcitabine Hydrochloride Plus Placebo | Other sarcoma participants | 11.1 | 95% Confidence Interval 1.4 to 34.7 | percentage of participants |
| Overall Survival | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | All Randomized | 11.0 | 95% Confidence Interval 9.6 to 20.7 | months |
| Overall Survival | Gemcitabine Hydrochloride Plus Placebo | All Randomized | 15.6 | 95% Confidence Interval 6.1 to 27.0 | months |
| Overall Survival | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Liposarcoma participants | 20.5 | 95% Confidence Interval 11.0 to NA | months |
| Overall Survival | Gemcitabine Hydrochloride Plus Placebo | Liposarcoma participants | 5.7 | 95% Confidence Interval 3.5 to NA | months |
| Overall Survival | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Other Sarcoma participants | 10.2 | 95% Confidence Interval 7.6 to 20.7 | months |
| Overall Survival | Gemcitabine Hydrochloride Plus Placebo | Other Sarcoma participants | 17.7 | 95% Confidence Interval 7.6 to 30.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01532687/results